METAVERSE WORLD FAKE WORLD

[mick]

#3-3 buyouts https://www.tipranks.com/news/article/3-biotech-stocks-to-buy-on-rna-revolution-bntx-cvac-arct?utm_source=advfn.com&utm_medium=referral


Arcturus Therapeutics (ARCT)

A global late-stage clinical mRNA medicines and vaccines company, Arcturus Therapeutics represents a bold bet on the future of advanced medical technologies. As with CureVac, Arcturus features proprietary technologies along with key partnerships with the broader aim to deliver innovative therapeutic solutions.


Currently, Arcturus is developing a COVID-19 vaccine specifically geared toward the omicron variant. As well, the biotech firm seeks solutions for long-term diseases and conditions. For example, Arcturus is collaborating with the Cystic Fibrosis Foundation to develop mRNA-based medicine to treat cystic fibrosis.


Nevertheless, prospective buyers of ARCT must be prepared for a potentially choppy ride, even stacked against higher-risk biotech stocks to buy. Shares are down roughly 58% year-to-date, reflecting tremendous volatility. However, Arcturus posted revenue of $27 million in Q2 2022, significantly outpacing the $2 million posted in the year-ago quarter.


Should investors have the patience and long-term outlook, ARCT could be intriguing as RNA-related biotech stocks rise on the success of the COVID-19 vaccine.


Is ARCT a Good Stock to Buy?

Turning to Wall Street, ARCT stock has a Hold consensus rating based on three Buys, three Holds, and two Sells assigned in the past three months. The average ARCT price target is $40.86, implying 175.71% upside potential.